GlassScriptPhysician profile
Benjamin J Askins
NPI 1679601330
$6,404.33
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,606 · 2020: $513 · 2021: $434 · 2022: $2,054 · 2023: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $704.45 | 2019-2023 | Breztri, Farxiga |
| Lilly USA, LLC | $570.57 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $536.18 | 2019-2023 | Wegovy, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $323.10 | 2019-2023 | Xifaxan, Trulance |
| Pfizer INC. | $312.07 | 2019-2023 | |
| Amgen INC. | $309.92 | 2019-2023 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.14 | 2019-2022 | |
| Abbvie INC. | $227.08 | 2019-2023 | Vraylar, Ubrelvy |
| Abbott Laboratories | $218.33 | 2019-2023 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $211.87 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $208.80 | 2019-2023 | Strensiq |
| Sanofi-Aventis U.S. LLC | $207.10 | 2019-2023 | |
| Amarin Pharma, INC. | $200.23 | 2019-2022 | |
| Baxter Healthcare | $192.62 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $192.01 | 2021-2023 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Askins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.